A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

[1]  J. Wolchok,et al.  Combination immunotherapy: a road map , 2017, Journal of Immunotherapy for Cancer.

[2]  Subbaya Subramanian,et al.  Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy. , 2017, Cancer research.

[3]  D. Mitchell,et al.  Manipulation of Innate and Adaptive Immunity through Cancer Vaccines , 2017, Journal of immunology research.

[4]  G. Beatty,et al.  Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists , 2017, Expert review of anticancer therapy.

[5]  Preeti Singh,et al.  The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression1 , 2017, Neoplasia.

[6]  M. Pittet,et al.  The role of myeloid cells in cancer therapies , 2016, Nature Reviews Cancer.

[7]  Chris Morrison.  Immuno-oncologists eye up macrophage targets , 2016, Nature Reviews Drug Discovery.

[8]  A. Ribas,et al.  Combination cancer immunotherapies tailored to the tumour microenvironment , 2016, Nature Reviews Clinical Oncology.

[9]  Xiaopei Huang,et al.  Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. , 2015, The Journal of clinical investigation.

[10]  S. Leung,et al.  HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer , 2015, Oncotarget.

[11]  M. Karin,et al.  Immunity, inflammation, and cancer: an eternal fight between good and evil. , 2015, The Journal of clinical investigation.

[12]  B. Baban,et al.  Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. , 2015, Cardiovascular research.

[13]  D. Linehan,et al.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.

[14]  L. Zitvogel,et al.  Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.

[15]  J. Chien,et al.  PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. , 2015, European journal of cancer.

[16]  W. Scheithauer,et al.  MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. , 2015, Critical reviews in oncology/hematology.

[17]  M. Glennie,et al.  Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study , 2015, Clinical Cancer Research.

[18]  D. Mukhopadhyay,et al.  The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine , 2014, Oncotarget.

[19]  T. Peretz,et al.  Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme. , 2014, Journal of the National Cancer Institute.

[20]  K. Kreamer.  Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer , 2014, Journal of the advanced practitioner in oncology.

[21]  E. Hammond,et al.  Heparanase cooperates with Ras to drive breast and skin tumorigenesis. , 2014, Cancer research.

[22]  D. V. Von Hoff,et al.  A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma , 2014, Clinical Cancer Research.

[23]  R. Brekken,et al.  PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer , 2013, Molecular Cancer Therapeutics.

[24]  Jonathan B. Mitchem,et al.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. , 2013, Cancer research.

[25]  R. Brandt,et al.  PG545, a Heparan Sulfate Mimetic, Reduces Heparanase Expression In Vivo, Blocks Spontaneous Metastases and Enhances Overall Survival in the 4T1 Breast Carcinoma Model , 2012, PloS one.

[26]  J. Grande,et al.  VEGF Inhibition, Hypertension, and Renal Toxicity , 2012, Current Oncology Reports.

[27]  N. Wimmer,et al.  Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis. , 2012, Journal of medicinal chemistry.

[28]  T. Gonda,et al.  PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models , 2011, British Journal of Cancer.

[29]  S. Endres,et al.  CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice , 2011, Clinical Cancer Research.

[30]  T. Gonda,et al.  The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy , 2010, Investigational New Drugs.

[31]  B. Redman,et al.  Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF‐3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma , 2009, Cancer.

[32]  Arthur M. Krieg,et al.  Toll-like receptor 9 (TLR9) agonists in the treatment of cancer , 2008, Oncogene.

[33]  S. Meijer,et al.  Intradermal CpG-B Activates Both Plasmacytoid and Myeloid Dendritic Cells in the Sentinel Lymph Node of Melanoma Patients , 2007, Clinical Cancer Research.

[34]  B. Pitt,et al.  CpG DNA-mediated immune response in pulmonary endothelial cells. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[35]  S J Schnitt,et al.  Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Scheulen,et al.  Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours. , 2015, European journal of cancer.

[37]  H. Choi,et al.  Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. , 2011, Biological & pharmaceutical bulletin.

[38]  J. Allison.  Immune Checkpoint Blockade in Cancer Therapy , 2008 .